XML 56 R46.htm IDEA: XBRL DOCUMENT v3.25.3
Note 12 - Commitments and Contingencies (Details Textual)
$ / shares in Units, $ in Thousands, € in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Aug. 31, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2020
USD ($)
shares
Mar. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
Nov. 30, 2024
USD ($)
Mar. 14, 2023
USD ($)
Mar. 31, 2020
Mar. 26, 2020
$ / shares
Share Price (in dollars per share) | $ / shares                   $ 6          
Inventory Step-Up                 $ 3,673 $ 0          
Increlex [Member]                              
Other Commitment       $ 2,500                      
Payments to Acquire Marketing Rights       22,500                      
Payments to Acquire Inventory $ 11,540     7,500                      
Business Combination, Contingent Consideration, Liability                 4,643            
Business Combination, Contingent Consideration, Liability, Accreted to Interest Expense                 357            
Number of Quarterly Installment Payments 8                            
Increlex [Member] | Accrued Liabilities [Member]                              
Business Combination, Contingent Consideration, Liability                 2,500            
Increlex [Member] | Other Noncurrent Liabilities [Member]                              
Business Combination, Contingent Consideration, Liability                 2,143            
Increlex [Member] | Accounts Payable, Current [Member]                              
Business Combination, Contingent Consideration, Liability $ 6,949                            
Increlex [Member] | Long-term Inventory Payable [Member]                              
Business Combination, Contingent Consideration, Liability $ 5,188                            
Indemnification Rights and Agreements [Member]                              
Other Commitment       $ 0         0            
Common Stock [Member]                              
Share Price (in dollars per share) | $ / shares                             $ 3.33
PKU GoLike [Member]                              
Other Commitment           $ 2,000                  
Payments to Acquire Marketing Rights           $ 2,200                  
Royalty on Net Sales of Products, Percent           30.00%                  
GALZIN [Member]                              
Royalties, Percentage of Net Sales,       10.00%                      
Payments to Acquire Marketing Rights       $ 7,000                      
GALZIN [Member] | Inventories [Member]                              
Payments to Acquire Marketing Rights       $ 200                      
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member]                              
Other Commitment                         $ 450    
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]                              
Royalties, Percentage of Net Sales,                         12.50%    
Other Commitment                         $ 200    
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]                              
Royalties, Percentage of Net Sales,                         17.00%    
Other Commitment                         $ 250    
Selenix [Member] | DS-200 [Member]                              
Proceeds From Up-front Payment         $ 500                    
Revenue, Additional Based on Event and Sales-based Milestones Achievements         $ 1,500                    
Commitment, Allocation of Profits, Percentage         45.00%                    
Selenix [Member] | DS-200 [Member] | Maximum [Member]                              
Revenue, Additional Based on Event and Sales-based Milestones Achievements               $ 5,000              
AMMTeK [Member] | Amglidia [Member]                              
Royalties, Percentage of Net Sales,                       14.00%      
AMMTeK [Member] | Amglidia [Member] | Receipt of FDA Minutes [Member]                              
Other Commitment                       $ 500      
AMMTeK [Member] | Amglidia [Member] | NDA Acceptance for Review by FDA [Member]                              
Other Commitment                       550      
AMMTeK [Member] | Amglidia [Member] | NDA Approval by the FDA and First Commercial Sale [Member]                              
Other Commitment                       $ 1,300      
Esteve [Member] | Increlex [Member]                              
Accounts Receivable, after Allowance for Credit Loss   $ 4,327           4,327              
Esteve [Member] | Increlex [Member]                              
Proceeds From Up-front Payment | €     € 4                        
License Agreement, Purchase Price of Option to Acquire | €     € 6                        
Revenues   1,786                          
Deferred Revenue   $ 2,541           $ 2,541              
Contract with Customer, Liability, Revenue Recognized                 322            
Inventory Step-Up                 3,673            
Esteve [Member] | Increlex [Member] | Accrued Liabilities [Member]                              
Deferred Revenue                 457            
Esteve [Member] | Increlex [Member] | Other Noncurrent Liabilities [Member]                              
Deferred Revenue                 $ 1,762            
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member]                              
Aggregate Value of Licensing Milestone Included in Research and Development Expense                     $ 1,000        
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | Maximum [Member]                              
Aggregate Value of Licensing Milestone Included in Research and Development Expense                     $ 44,000        
Royalties, Percentage of Net Sales,                           17.00%  
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | Minimum [Member]                              
Royalties, Percentage of Net Sales,                           11.50%  
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | Common Stock [Member]                              
Stock Issued During Period, Shares, New Issues (in shares) | shares             379,474                
Stock Issued During Period, Value, New Issues             $ 1,264                
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | License [Member]                              
Commitment, Milestone Fee             $ 3,500